Fuse Launches Flip Product Range for Rapid Point-of-Need Diagnostics
First product Flip Mycoplasma detects cell culture contamination with unrivalled speed, accuracy and simplicity
Fuse Diagnostics has today announced that it has launched Flip; a revolutionary new range of diagnostic tests that deliver laboratory accuracy in a simple, single-use format for rapid point-of-need pathogen testing across industry.
Flip Mycoplasma, the first product in the new range, is a breakthrough test that delivers laboratory PCR quality results in just 12 minutes, enabling ultra-rapid detection of Mycoplasma contamination in cell cultures. Designed to help eliminate reproducibility and quality issues in cell biology research and bioprocessing, it empowers end users to take immediate action - saving valuable time and reducing costs.
Fuse is developing a range of other Flip tests that address critical needs for rapid onsite testing within the industrial, food, water and veterinary sectors, including tests for Legionella and Avian Influenza. Flip tests are provided in a ready-to-use format and exhibit exceptional diagnostic performance giving a clear visual result read-out in just minutes without any complex equipment or processing.
Fuse CEO Dr Harry Lamble said: “Flip is a transformative solution for rapid onsite testing that brings gold standard laboratory performance into a small, low-cost, disposable device format that anyone can use. We look forward to complementing Flip Mycoplasma with a range of other tests that allow users to overcome the delay and complexity of existing centralised instrument-based testing.”
In 2024, Fuse announced that it had raised £1.6 million in an oversubscribed seed investment round, and a separate $1 million award from CARB-X, to develop its diagnostic testing platforms. In addition to the Flip product range, Fuse is investing in developing Apex, a fully integrated instrument-free test for point-of-care clinical diagnostic applications such as respiratory and sexually transmitted infections.